v3.25.2
Segment Reporting - Schedule of reconciliation of the Company's net loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2024
Mar. 31, 2024
Jun. 30, 2025
Jun. 30, 2024
Operating revenue by external customer:            
Sanofi collaboration revenue $ 143,623   $ 1,254   $ 144,122 $ 1,751
Operating expenses:            
Research and development 5,863   41,962   28,200 85,777
General and administrative 9,581   10,649   20,630 21,187
Impairment and disposal of long-lived assets 31,917   0   53,806 0
Other income:            
Interest income 1,322   3,455   3,206 7,495
Net Income (Loss) 97,584 $ (52,892) (47,902) $ (49,816) 44,692 (97,718)
Imvotamab - Autoimmune Programs [Member]            
Operating expenses:            
Research and development [1] (215)   2,522   2,522 5,393
Aplitabart - Deprioritized Program [Member]            
Operating expenses:            
Research and development [1] (418)   8,976   1,367 16,748
Other Discontinued Programs [Member]            
Operating expenses:            
Research and development [1] (3)   1,529   (207) 5,255
Preclinical and Other Research and Development [Member]            
Operating expenses:            
Research and development [2] 1,802   5,394   3,689 12,102
Personnel [Member]            
Operating expenses:            
Research and development 3,104   16,907   14,507 33,405
General and administrative 4,648   7,236   11,619 14,238
Depreciation and Facilities [Member]            
Operating expenses:            
Research and development 1,593   6,634   6,322 12,874
Other General and Administrative [Member]            
Operating expenses:            
General and administrative [3] $ 4,933   $ 3,413   $ 9,011 $ 6,949
[1] Discontinued clinical program expenses were primarily driven by the wind down of aplitabart and other discontinued programs, including imvotamab in oncology and autoimmune diseases, IGM-2644 in oncology and autoimmunity, and IGM-7354, and the receipt of refunds from certain CROs.
[2] Preclinical and other R&D expense includes sample analysis, preclinical testing, R&D licensing agreements, and drug product services.
[3] Other general and administrative expense includes professional services, accounting services, software, rent, and other overhead expense.